Patient Reported Outcomes (PRO) in patients (pts) with HER2-advanced   breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) receiving   talazoparib (TALA) vs physician's choice chemotherapy (PCT) in the   EMBRACA trial: A focus on subgroups with/without visceral disease

Dokumenttyp:: Meeting Abstract
Autor(en):: Ettl, J.; Quek, R. G. W.; Bhattacharyya, H.; Rugo, H. S.; Hurvitz, S. A.; Goncalves, A.
Titel:: Patient Reported Outcomes (PRO) in patients (pts) with HER2-advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician's choice chemotherapy (PCT) in the EMBRACA trial: A focus on subgroups with/without visceral disease
Zeitschriftentitel:: Ann Oncol
Jahr:: 2019
Band / Volume:: 30 Suppl 5
Seitenangaben Beitrag:: 129-+
Print-ISSN:: 0923-7534
TUM Einrichtung:: Frauenklinik und Poliklinik
BibTeX

Vorkommen: